Compare Stocks: XRTX, ENVB, LIAN, and MBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENVB Enveric Biosciences	$1.42 +2.9%	$1.45	$1.17 ▼ $13.25	$6.36M	1.18	1.33 million shs	56,486 shs
LIAN LianBio	$0.06	$0.05	$0.27 ▼ $4.99	$6.43M	0.23	1.04 million shs	N/A
MBRX Moleculin Biotech	$9.27 +30.7%	$11.04	$3.23 ▼ $315.00	$9.55M	2	33,499 shs	186,345 shs
XRTX XORTX Therapeutics	$1.10 +3.8%	$1.79	$0.83 ▼ $3.65	$2.00M	0.78	612,433 shs	39,167 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENVB Enveric Biosciences	-1.43%	-0.72%	-8.00%	+3.76%	-81.69%
LIAN LianBio	0.00%	+16.67%	0.00%	+19.00%	-15.00%
MBRX Moleculin Biotech	+9.08%	+33.77%	-41.07%	-83.81%	-97.08%
XRTX XORTX Therapeutics	+15.20%	+4.95%	-37.28%	-48.29%	-67.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENVB Enveric Biosciences	$1.42 +2.9%	$1.45	$1.17 ▼ $13.25	$6.36M	1.18	1.33 million shs	56,486 shs
LIAN LianBio	$0.06	$0.05	$0.27 ▼ $4.99	$6.43M	0.23	1.04 million shs	N/A
MBRX Moleculin Biotech	$9.27 +30.7%	$11.04	$3.23 ▼ $315.00	$9.55M	2	33,499 shs	186,345 shs
XRTX XORTX Therapeutics	$1.10 +3.8%	$1.79	$0.83 ▼ $3.65	$2.00M	0.78	612,433 shs	39,167 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENVB Enveric Biosciences	-1.43%	-0.72%	-8.00%	+3.76%	-81.69%
LIAN LianBio	0.00%	+16.67%	0.00%	+19.00%	-15.00%
MBRX Moleculin Biotech	+9.08%	+33.77%	-41.07%	-83.81%	-97.08%
XRTX XORTX Therapeutics	+15.20%	+4.95%	-37.28%	-48.29%	-67.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENVB Enveric Biosciences	1.00	Sell	N/A	N/A
LIAN LianBio	0.00	N/A	N/A	N/A
MBRX Moleculin Biotech	2.33	Hold	$60.00	547.25% Upside
XRTX XORTX Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XRTX, ENVB, LIAN, and MBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	ENVB Enveric Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/15/2026	MBRX Moleculin Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/21/2026	XRTX XORTX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/28/2026	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$60.00

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$7.00 per share	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$93.81 per share	N/A
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	$1.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENVB Enveric Biosciences	-$8.77M	-$12.65	N/A	N/A	N/A	N/A	-168.04%	-145.95%	11/12/2026 (Estimated)
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
MBRX Moleculin Biotech	-$33.56M	-$7.13	N/A	N/A	N/A	N/A	-143.51%	-24.53%	11/12/2026 (Estimated)
XRTX XORTX Therapeutics	-$2.66M	-$2.73	N/A	N/A	N/A	N/A	-137.85%	-108.16%	11/12/2026 (Estimated)

Latest XRTX, ENVB, LIAN, and MBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	MBRX Moleculin Biotech	-$8.8667	N/A	N/A	N/A	N/A	N/A
8/15/2026	Q2 2026	XRTX XORTX Therapeutics	N/A	-$1.05	N/A	-$1.05	N/A	N/A
8/14/2026	Q2 2026	ENVB Enveric Biosciences	N/A	-$0.76	N/A	-$0.76	N/A	N/A
8/13/2026	Q2 2026	MBRX Moleculin Biotech	-$31.00	-$28.00	+$3.00	-$1.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENVB Enveric Biosciences	N/A	10.21	10.21
LIAN LianBio	N/A	10.06	10.06
MBRX Moleculin Biotech	N/A	0.94	0.94
XRTX XORTX Therapeutics	N/A	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENVB Enveric Biosciences	13.82%
LIAN LianBio	74.85%
MBRX Moleculin Biotech	15.52%
XRTX XORTX Therapeutics	0.23%

Insider Ownership

Company	Insider Ownership
ENVB Enveric Biosciences	2.41%
LIAN LianBio	7.59%
MBRX Moleculin Biotech	18.04%
XRTX XORTX Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENVB Enveric Biosciences	6	4.48 million	4.37 million	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
MBRX Moleculin Biotech	17	1.03 million	842,000	Not Optionable
XRTX XORTX Therapeutics	N/A	1.82 million	1.69 million	Not Optionable

XRTX, ENVB, LIAN, and MBRX Headlines

Recent News About These Companies

XORTX stock: XORTX outlines Canadian trial plan before stock results

October 23, 2026 | ad-hoc-news.deA

XORTX Therapeutics Inc XRTX

October 16, 2026 | morningstar.comM

XORTX outlines Canadian trial plan for XORTX Therapeutics stock

October 15, 2026 | ad-hoc-news.deA

XORTX Plans Canadian Trial Of Gout Drug XORLO To Support Future U.S. NDA Filing; Stock Up

October 9, 2026 | rttnews.com

XORTX plans Health Canada application for gout drug XRx-026

October 8, 2026 | streetinsider.com

Xortx Therapeutics Shares Rise After Company Reports Potential Partner Interest for Gout Program

October 8, 2026 | finance.yahoo.com

XORTX Therapeutics stock gained 1.76 percent as FDA plan advances

October 8, 2026 | ad-hoc-news.deA

XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout

October 8, 2026 | financialpost.comF

Gout Treatments Need A Better Option: XORTX Therapeutics Is Betting XORLO Is It, Targets New Drug Application With FDA Next Year

October 7, 2026 | newmediawire.comN

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market Opportunity

September 19, 2026 | barrons.com

XORTX Therapeutics Shares Rise 12% On IND Submission Plan

September 19, 2026 | rttnews.com

XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year

September 18, 2026 | rttnews.com

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

September 18, 2026 | globenewswire.com

XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%

September 11, 2026 | rttnews.com

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

September 10, 2026 | financialpost.comF

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

September 10, 2026 | globenewswire.com

XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile

September 8, 2026 | tipranks.com

XORTX Re-Engages Investor Relations Program

September 8, 2026 | financialpost.comF

XORTX Re-Engages Investor Relations Program

September 8, 2026 | globenewswire.com

XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed

August 28, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XRTX, ENVB, LIAN, and MBRX Company Descriptions

Enveric Biosciences NASDAQ:ENVB

$1.42 +0.04 (+2.90%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 +0.03 (+1.76%)

As of 07:43 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

LianBio NASDAQ:LIAN

$0.06 0.00 (0.00%)

As of 10/26/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Moleculin Biotech NASDAQ:MBRX

$9.27 +2.18 (+30.75%)

Closing price 04:00 PM Eastern

Extended Trading

$9.57 +0.30 (+3.21%)

As of 07:43 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

XORTX Therapeutics NASDAQ:XRTX

$1.10 +0.04 (+3.77%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 -0.02 (-1.36%)

As of 07:30 PM Eastern

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XRTX, ENVB, LIAN, and MBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XRTX, ENVB, LIAN, and MBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XRTX, ENVB, LIAN, and MBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XRTX, ENVB, LIAN, and MBRX Company Descriptions

Enveric Biosciences NASDAQ:ENVB

LianBio NASDAQ:LIAN

Moleculin Biotech NASDAQ:MBRX

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XRTX, ENVB, LIAN, and MBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XRTX, ENVB, LIAN, and MBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XRTX, ENVB, LIAN, and MBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XRTX, ENVB, LIAN, and MBRX Company Descriptions

Enveric Biosciences NASDAQ:ENVB

LianBio NASDAQ:LIAN

Moleculin Biotech NASDAQ:MBRX

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools